GH Research PLC

US$18.61As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:GHRSHealthcare
Country USA
PE (Fwd) •••
TSR 5Y CAGR (2.85%)
Div yield —
ROE (18.79%)
Biotechnology
Beta (5Y) 1.32
PE TTM —
TSR TTM 29.96%
Mkt cap US$1.277B
ROIC (13.45%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$21
13.38%
(23.47%)
Hold 8|10|2|12|5
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.32
0.34
0.35
0.37
11.70%
25.37%
22.81%
21.58%
Revenue$M
105.2
108.5
106.6
106.5
9.36%
11.72%
3.95%
(0.25%)
Peers (US$1.277B)
Cap (US$)
PE
Capital
TTM
5Y
10Y
Leveragex
0.385
(0.058)
(0.037)
EBIT/Intx
0.262
1.289
0.854
Own earn%
1.25
(102.16)
(99.75)
Sh yield%
37.44
2.86
3.41
Owners
Insiders/Inst%
5.28
34.66
Short interest%
2.36
SBC / revenue%
3.22
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
21
Op margin range%
20–22
$1 testx
0.0
Incr. ROIC%
68